Related by context. All words. (Click for frequent words.) 64 pharmacodynamic properties 64 galiximab 63 pharmacokinetic profiles 63 Pharmacokinetic parameters 62 Seliciclib 60 antiangiogenic activity 60 pharmacokinetic characteristics 60 pharmacokinetic equivalence 60 Zevalin consolidation 59 plus prednisone prednisolone 59 MAGE A3 ASCI 59 Ceplene/IL-2 59 bovine thrombin 59 gemcitabine cisplatin 59 retapamulin 59 5 FU leucovorin 59 gemcitabine carboplatin 59 pharmacodynamic profiles 59 Non inferiority 59 xenograft models 59 Targretin capsules 59 Epivir HBV 59 pomalidomide 58 neratinib 58 pegylated interferons 58 unique alkylating agent 58 prednisone prednisolone plus 58 oxazolidinone 58 MET amplification 58 Cloretazine R VNP#M 58 Taxotere chemotherapy 58 Amrubicin 58 oral antidiabetic 58 sorafenib Nexavar ® 58 proteasome inhibitor 58 Xanafide 58 K ras mutations 58 COMPARATIVE FIGURES Certain 58 tigecycline 58 relapsed MM 58 ENMD # 57 sorafenib Nexavar 57 preclinically 57 mapatumumab 57 plus prednisone 57 Daptomycin 57 indibulin 57 fusion enhancers 57 Cetrorelix pamoate 57 trastuzumab emtansine T DM1 57 CANCIDAS 57 Panzem R NCD 57 HGS ETR1 mapatumumab 57 potency selectivity 57 metaglidasen 57 fluoropyrimidine 57 Darinaparsin 57 carboplatin paclitaxel 57 TOCOSOL Camptothecin 57 Cloretazine 57 BFPET 57 Xeloda ® 57 antiresorptive 57 active comparator 57 gadobutrol 56 sorafenib tablets 56 VELCADE melphalan 56 radiation sensitizer 56 OncoVEX GM CSF 56 Munghana Lonene Listenership 56 elacytarabine 56 PITX2 methylation 56 Bayer HealthCare Onyx Pharmaceuticals 56 thalidomide Thalomid 56 ritonavir boosted protease inhibitor 56 Allovectin 7 ® 56 Platinol ® cisplatin 56 nilotinib Tasigna ® 56 oral Hycamtin 56 trastuzumab Herceptin R 56 antiviral efficacy 56 dose pravastatin 56 PSMA ADC 56 mycophenolate mofetil 56 oral talactoferrin 56 maximally tolerated dose 56 pharmacokinetic pharmacodynamic 56 concurrent chemoradiation 56 Neuradiab 56 Triapine R 56 FOLFOX6 chemotherapy regimen 56 EZN 56 genotypic resistance 56 hemostatic efficacy 56 idraparinux 56 Dabigatran etexilate 56 evaluating tivozanib 56 YONDELIS 56 liposomal doxorubicin 56 conditional logistic regression 56 potent triglyceride lowering 56 pharmacodynamic markers 56 dasatinib Sprycel 56 Tumor Response 56 metastatic HRPC 56 tecarfarin 56 low dose cytarabine 56 erlotinib Tarceva ® 56 pharmacodynamics PD 56 hypoxia selective 56 dacarbazine chemotherapy 56 PegIFN 55 HIV RDEA# 55 sitagliptin Januvia 55 MabCampath 55 neurologic progression 55 ® bortezomib 55 docetaxel Taxotere ® 55 active moiety 55 clomipramine 55 pharmacokinetics PK 55 pegnivacogin 55 inactivated strain 55 APTIMA HPV assay 55 plasma kallikrein inhibitor 55 APTIMA HPV 55 erythropoietic 55 Tarceva TM 55 CCR5 receptor antagonist 55 demonstrated antitumor activity 55 sapacitabine CYC# 55 Adrian Guelke professor 55 refractory multiple myeloma 55 Velcade bortezomib 55 alvespimycin 55 Aplidin 55 Taxol ® 55 antitumor effect 55 xanthine oxidase inhibitor 55 radiation dosimetry 55 Silodosin 55 Oral NKTR 55 BAY #-# 55 EGFR HER2 55 prospectively stratified 55 bicalutamide 55 HIV coinfected 55 noninferiority 55 NOXAFIL Oral Suspension 55 dacarbazine 55 Interferon alfa 55 potent antitumor activity 55 CCX# 55 Zemplar Capsules 55 SS NOI helps 55 IMPDH inhibitor 55 novel oral anticoagulant 55 Cariprazine 55 melphalan prednisone 55 pharmacodynamic PD 55 CaPre TM 55 pegylated liposomal doxorubicin 55 pharmacokinetic properties 55 postoperative chemotherapy 55 Nambu theories permeate 55 Fludara 55 SERMs 55 oral ridaforolimus 55 titrated glipizide 55 Pemetrexed 55 docetaxel chemotherapy 55 potent topoisomerase II 55 cariprazine 55 Epirubicin 55 clevidipine 55 Zoraxel TM 55 Cloretazine ® 55 DOXIL 55 Umbilical cord stem cells 55 OncoVEX 55 small molecule Hedgehog 55 oral rivaroxaban 54 temsirolimus 54 venlafaxine XR 54 sensitivity specificity 54 KRAS status 54 antiandrogens 54 cobas HPV Test 54 HGS ETR2 54 preclinical efficacy 54 mertansine 54 ANAVEX #-# [001] 54 tolerability profiles 54 vincristine adriamycin 54 daunorubicin 54 Phase Ib study 54 bendamustine 54 pharmacologic stress 54 pain palliation 54 fosbretabulin 54 BRIM3 54 pharmacokinetic parameters 54 Vectibix panitumumab 54 amphotericin 54 paclitaxel carboplatin 54 Logistic regression 54 tolerability pharmacokinetics 54 serum biomarkers 54 topical antifungal 54 aflibercept VEGF Trap 54 bioequivalency 54 docetaxel 54 paclitaxel Taxol ® 54 oral chemotherapeutic agent 54 Exelixis compounds 54 radezolid 54 anidulafungin 54 protease inhibitor PI 54 EmbraceAC 54 PDX pralatrexate 54 viral kinetics 54 mRCC 54 bortezomib Velcade R 54 Virulizin ® 54 NNRTIs 54 pharmacokinetic interactions 54 chlorambucil 54 Pharmacokinetic studies 54 Bonferroni correction 54 gemtuzumab ozogamicin 54 5-FU/LV 54 antithrombotic 54 oral picoplatin 54 nonnucleoside reverse transcriptase inhibitors 54 dose Iluvien 54 FUSILEV enhances 54 macrolide antibiotic 54 NS5B polymerase 54 Omacetaxine 54 regorafenib 54 antianginal 54 Pertuzumab 54 Pazopanib 54 Post hoc 54 irinotecan doxorubicin oxaliplatin paclitaxel 54 BR.# 54 analgesic efficacy 54 SYNERGY Stent 54 posaconazole 54 immune modulating 54 ganetespib 54 nonclinical studies 54 Arsenic trioxide 54 QTc prolongation 54 lenalidomide Revlimid R 54 Q#IR 54 DEB# 54 iniparib 54 locoregional recurrence 54 combinability 54 ARB telmisartan 54 refractory chronic lymphocytic 54 enzyme immunoassay EIA 54 JAK inhibitor 54 induced tumor regression 54 Randomized trials 54 Lenocta TM sodium stibogluconate 54 NMIBC 54 IV bisphosphonates 54 doxorubicin cyclophosphamide 54 oral diclofenac 54 LAB CGRP 54 radiolabeled monoclonal antibody 53 interferon alfa 2b 53 ZYBRESTAT fosbretabulin 53 lenalidomide Revlimid 53 Meta analyzes 53 Engerix B 53 CTAP# Capsules 53 dacarbazine DTIC 53 plasma pharmacokinetics 53 oxaliplatin Eloxatin 53 chemotherapy gemcitabine 53 Anticalins ® 53 oral gallium 53 adjuvant therapies 53 intravesical infusion therapy 53 receptor tyrosine kinase inhibitor 53 XELOX 53 zotarolimus 53 LT NS# 53 Tesmilifene 53 multivariate Cox 53 QT QTc 53 HCV protease inhibitors 53 factor Xa inhibitor 53 ToGA 53 hemagglutination inhibition 53 ertapenem 53 univariate 53 adriamycin 53 Kahalalide F 53 purity potency 53 anticancer activity 53 pharmacodynamic parameters 53 lumiliximab 53 R sorafenib tablets 53 trans retinoic acid ATRA 53 vinca alkaloid 53 REMINYL ® 53 DNAWitness Mito 53 novel nucleoside analog 53 Aflibercept 53 seroprotection 53 randomized multicentre 53 chemotherapy cisplatin 53 heparanase 53 Fulvestrant 53 adenosine injection 53 Phase 1b clinical trials 53 ancrod 53 Afatinib 53 co receptor tropism 53 HER2 overexpression 53 Gemcitabine 53 Anticalins R 53 PrevOnco 53 generation Hsp# inhibitor 53 EGFR mutation positive 53 SUTENT ® 53 Deforolimus 53 doxorubicin HCl liposome injection 53 antiviral potency 53 Alocrest 53 Cytoxan 53 BEXXAR Therapeutic Regimen 53 Octreolin 53 NovoTTF 53 MoxDuo ® IR 53 imipenem 53 cefepime 53 aflibercept 53 dose proportionality 53 overlapping toxicities 53 echinocandin 53 bronchial lavage 53 Zolinza 53 nonselective NSAIDs 53 TAXUS VI 53 Cervista HPV HR 53 PEGylated interferon 53 peg IFN 53 fulvestrant 53 elvitegravir 53 pegylated interferon alfa 53 teriflunomide 53 Thalomid ® 53 nonsquamous 53 immunomodulator 53 PREZISTA r 53 Capecitabine 53 Hycamtin ® 53 5 fluorouracil leucovorin 53 anthracycline taxane 53 calcineurin inhibitors 53 EOquin TM 53 F FDG PET 53 Androxal TM 53 microbiological eradication 53 adipiplon 53 busulfan 53 angiographic outcomes 53 sargramostim 53 Vidaza ® 53 Septin9 biomarker 53 abacavir lamivudine 53 CYT# vascular disrupting 53 pharmacokinetics pharmacodynamics 53 Canvaxin TM 53 CIMZIA ™ 53 Phase Ib II 53 UroVysion 53 histone deacetylase HDAC inhibitor 53 CYT# potent vascular disrupting 53 radiotherapy RT 53 pertuzumab 53 Budesonide foam crofelemer 53 zoledronate 53 HCV RESPOND 2 53 refractory AML 53 LymphoStat B belimumab 53 locoregional 53 multicenter multinational 53 plasma renin activity 53 Oracea TM 53 Bezielle 53 Peginterferon alfa 2b 53 Peg IFN 53 UPLYSO 53 FOLFOX4 53 doripenem 53 Poisson regression 53 VNP#M 53 effector function 53 Multivariate logistic regression 53 PDE4 inhibitors 53 bactericidal activity 53 pharmacologically active isomer 53 oxaliplatin 53 idarubicin 53 PI3K/Akt pathway inhibitor 53 Onrigin 53 tenofovir emtricitabine 53 insulin sensitizing 53 Subgroup analysis 53 delafloxacin 53 unfractionated heparin UFH 53 ratio ICER 53 CHOP chemotherapy 53 urine cytology 53 subcutaneous PRO 53 haematologic 53 virus HCV protease inhibitor 53 ritonavir boosted 53 Folfox 53 thymalfasin 53 efavirenz EFV 53 sunitinib malate 53 favorable pharmacokinetic profile 53 dimeglumine 53 recombinant interferon 53 MoxDuo TM IR 53 Anidulafungin 53 maximally tolerated 53 Hexvix 52 octreotide LAR 52 ADAGIO study 52 urinary N telopeptide 52 dexamethasone Decadron 52 GAMMAGARD 52 Amplimexon 52 AAG geldanamycin analog 52 OMS# 52 pCR 52 HMG CoA reductase inhibitor 52 enzastaurin 52 BioMatrix TM 52 AKT inhibitor 52 MIRCERA 52 intravesical 52 CALGB 52 secretory phospholipase A2 52 RhuDex ® 52 Doxil ® 52 surrogate endpoint 52 IGF 1R inhibitor 52 OMP #M# 52 recurrent metastatic ovarian cancer 52 EGS# 52 docetaxel Taxotere R 52 metastatic androgen independent 52 boosted protease inhibitor 52 topotecan 52 investigational protease inhibitor 52 HCV replicon 52 NeuroSTAT ® 52 conventional DMARDs 52 anti leukemic 52 Perforomist ™ Inhalation Solution 52 prospectively defined 52 Fludara ® 52 Ixempra 52 DXL TM antibodies 52 Anturol TM 52 Femara letrozole 52 Empatic ™ 52 antifolates 52 HQK 52 oral deforolimus 52 Phase III randomized controlled 52 irbesartan 52 goserelin 52 IMiDs ® 52 topical antimicrobial 52 trabectedin 52 BN# [004] 52 treat chronic rhinosinusitis 52 cardiac toxicity 52 Dasatinib 52 CHAMPION PCI 52 atorvastatin #mg 52 caspofungin 52 randomized Phase 2b 52 BYETTA exenatide injection 52 Radical prostatectomy 52 statin simvastatin 52 KNS # 52 selective kinase inhibitor 52 nonsmall cell lung cancer 52 trials RCTs 52 CAELYX 52 azilsartan medoxomil 52 Specifid 52 Telik logo TELINTRA 52 TPI ASM8 52 mTOR inhibitors 52 Rigorous scientific 52 ARCALYST ® 52 reboxetine 52 successfully commercialize Iluvien 52 antiretroviral naïve 52 oral prodrug 52 Panzem R 52 vorinostat 52 TLR9 agonists 52 Androgel R 52 gemcitabine 52 cobicistat 52 MEK inhibitors 52 hematological parameters 52 urate lowering 52 Shark cartilage 52 trastuzumab DM1 T DM1 52 bleomycin 52 BioNeutral antimicrobial formulations 52 Telatinib 52 statistically significant superiority 52 targeting moieties 52 Subgroup analyzes 52 bevirimat Study 52 somatostatin analogues 52 apremilast 52 d l leucovorin 52 candidates Azedra TM 52 pegylated interferon alpha 52 clinicopathological features 52 Flow cytometry 52 recombinant PSMA vaccine 52 ZACTIMA 52 cytarabine daunorubicin 52 biostatistical analysis 52 Kaplan Meier analysis 52 CD# antibodies 52 EDEMA3 trial 52 SB# ONX 52 HCV SPRINT 52 Hexvix ® 52 NMP# 52 bortezomib Velcade 52 ceftazidime 52 Tipranavir 52 microbiologically evaluable 52 AST ALT 52 bendamustine ifosfamide 52 pharmacodynamic effects 52 recurrent NSCLC 52 next generation URAT1 52 eribulin mesylate 52 MacroChem actual 52 protein kinase inhibitor 52 ELISpot 52 NSABP C 52 HCV antiviral 52 SCH # 52 Rigel R# 52 anastrazole 52 cisplatin gemcitabine 52 orally administered inhibitor 52 KRAS mutation status 52 ALIMTA cisplatin 52 BARACLUDE R 52 riociguat 52 recurrent metastatic 52 ZOLINZA 52 statistical significance p 52 PV module efficiencies 52 Sanofi Aventis Taxotere 52 TNF inhibitor 52 neovascular diseases 52 Cytolin R 52 telaprevir dosed 52 Oncotype DX colon cancer 52 dasatinib Sprycel ® 52 prospective randomized multicenter 52 deCODE ProstateCancer TM 52 rNAPc2 52 Zysolin TM 52 fluvastatin 52 pharmacodynamics 52 tubulin inhibitor 52 5FU 52 ritonavir boosted atazanavir 52 Haptoglobin 52 CLARITY study 52 plus dacarbazine 52 estramustine 52 Aclidinium 52 CEDC discusses 52 Faslodex 52 huN# DM1 52 ginkgo extract 52 RECORD1 52 CDK inhibitor 52 infliximab monotherapy 52 sleeve lobectomy 52 TH# [003] 52 reactogenicity 52 miRview ™ squamous 52 linezolid 52 TELCYTA 52 EGFR mutation status 51 eplerenone 51 anti resorptive 51 CRMD# 51 tumor vascular disrupting 51 lorvotuzumab mertansine 51 JVRS 51 Taxotere ® 51 Genentech Tarceva 51 achieved statistical significance 51 oral proteasome inhibitor 51 EpiCeram TM 51 multicenter Phase II 51 dosimetric 51 efficacy 51 immunosuppressive regimens 51 Phase Ib IIa 51 web site http:/www.nasd-law.com/documents/classvrIcy Cape 51 Valortim ® 51 Visipaque 51 Selzentry TM 51 Dapoxetine 51 complete cytogenetic response 51 ACAPODENE TM 51 recurrent GBM 51 decitabine 51 Vaxfectin R 51 mTOR inhibitor 51 platelet inhibitor 51 EOquin 51 peginterferon alfa 2b 51 endoscopic gastric ulcers 51 Erlotinib 51 Genz # 51 neuropathy sparing 51 targets VEGFR EGFR 51 immunotherapeutic agent 51 cyclin dependent kinase CDK 51 Bafetinib 51 sorafenib Nexavar R 51 plus dexamethasone 51 sulindac 51 HCV NS5B polymerase 51 Eloxatin ® 51 bortezomib 51 biodistribution 51 tipifarnib 51 Procoralan 51 intracellular uptake 51 GW# [003] 51 MoxDuo 51 CCR9 antagonist 51 histologies 51 LEP ETU 51 TLR7 agonist 51 seliciclib 51 multivariable Cox 51 placebo controlled multicenter 51 generation nucleoside analog 51 multicenter randomized placebo controlled 51 monotherapies 51 EDEMA3 51 adefovir dipivoxil 51 viral kinetic 51 Gemzar ® 51 Thiarabine 51 antithrombotics 51 INTELENCE 51 cleavable linker 51 bronchodilatory 51 rilonacept 51 Azedra 51 AEG# 51 DAVANAT 51 plus gemcitabine 51 antirheumatic 51 PegIFN RBV 51 evaluating Vectibix 51 rFSH 51 demonstrated clinically meaningful 51 CCR5 inhibitor 51 bepotastine besilate nasal spray 51 Phase Ib clinical 51 paricalcitol 51 SRT# [003] 51 Arranon 51 website www.aceto.com 51 RoACTEMRA 51 solithromycin 51 saline placebo 51 FOLPI 51 gp# vaccine 51 pharmacodynamic profile 51 refractory metastatic colorectal cancer 51 oncologic outcomes 51 liposomal formulation 51 EOquin TM phase 51 ACE inhibitor ramipril 51 FullTerm 51 Sensitivity specificity 51 intra arterial chemotherapy 51 Betaseron ® 51 HBeAg seroconversion 51 TBC# 51 beta lactams 51 q8h 51 efficacy endpoint 51 NeoRecormon 51 Multiple logistic regression 51 liposomal amphotericin B 51 immunohistochemical analysis 51 coronary stent merged 51 transfection efficiency 51 REVIVE Diabetes 51 dose dexamethasone 51 BRAF inhibitor 51 FOLFIRI 51 percutaneous cryoablation 51 efficacy tolerability 51 lisdexamfetamine dimesylate 51 Tanespimycin KOS 51 NanoCrystal Technology 51 adjuvant GIST 51 phase IIb study 51 Carvedilol 51 PANVAC VF 51 Onco TCS 51 R# #mg BID 51 CCR5 antagonist 51 olmesartan 51 mimicked saliva 51 cytotoxic chemotherapy 51 Regadenoson 51 temozolomide TMZ 51 piperacillin tazobactam 51 SCIg 51 GLASSIA 51 davunetide intranasal AL 51 Solorel TM 51 topical gel containing 51 Ganciclovir 51 COPEGUS 51 PXA signal 51 darunavir ritonavir 51 systemically administered 51 CR nPR 51 Prodarsan ® 51 rifalazil 51 X ray angiography 51 sirtuin modulators 51 Traficet EN 51 intravesical therapy 51 Hormone receptor 51 massive sulphide ores 51 TRIOLEX HE# APOPTONE HE# 51 GP IIb IIIa inhibitors 51 Diamyd r vaccine 51 multivariate logistic regression 51 oxcarbazepine 51 Randomized clinical trials 51 Navelbine ® 51 miconazole Lauriad ® 51 Xelox 51 Vaxfectin TM 51 XP# XP# 51 Archexin 51 Mg Usa 51 soft gelatin capsule 51 GSK# [001] 51 tamoxifen Nolvadex ® 51 ritonavir boosted lopinavir 51 gemcitabine chemotherapy 51 vinorelbine 51 Randomised 51 tapentadol IR 51 vincristine doxorubicin 51 antitumor efficacy 51 oral clodronate 51 aspirin clopidogrel 51 pulp metallic 51 Nexavar sorafenib tablets 51 PREZISTA rtv 51 KRAS wild 51 maximal tolerated 51 nucleoside reverse transcriptase inhibitor 51 small molecule chemotherapeutic 51 Eraxis 51 antitumor activity 51 PRIMO CABG 51 reduce serum phosphate 51 APTIVUS r 51 DepoDur TM 51 PROSTASCINT R 51 Omacetaxine mepesuccinate 51 RE LY ® 51 Vidofludimus 51 registrational Phase 51 endothelin receptor antagonists 51 prospective randomized placebo 51 XL# anticancer compounds 51 Elvitegravir 51 DMXAA 51 SIR Spheres 51 alfa 2a 51 vidofludimus 51 ACR# responses 51 bazedoxifene 51 brivanib 51 Torisel 51 eTag assays 51 DACH platinum 51 hypoxia activated prodrug 51 Phase 2b randomized 51 FOSRENOL ® 51 tumor xenograft models 51 TURBT 51 histone deacetylase inhibitor 51 myelofibrosis polycythemia vera 51 Vicinium TM 51 relapsed SCLC 51 non nucleoside inhibitor 51 AGHD 51 tanespimycin 51 chemoprevention trials 51 intravenous dosing 51 EGFR TKI 51 MoxDuo ® 50 Etravirine 50 elvucitabine 50 conventional nebulized budesonide 50 DNAWitness Y 50 XIENCE V PROMUS Stent 50 PROCRIT ® 50 Diovan HCT 50 glatiramer acetate Copaxone 50 pegylated alpha interferon 50 ara C 50 dose escalation trial 50 2 methoxyestradiol 50 dose atorvastatin 50 prognostic indicators 50 CEQ# 50 thorough QT 50 darunavir 50 ongoing Phase 1b 50 Mg Uk 50 epirubicin cyclophosphamide 50 everolimus eluting stent 50 axitinib 50 trastuzumab 50 Muraglitazar 50 Capesaris 50 metastatic RCC 50 CorVue ™ 50 mitomycin 50 MoxDuo IR 50 TTF Therapy 50 accumulate preferentially 50 cisplatin vinorelbine 50 chemotherapy docetaxel 50 BrachySil 50 deCODE AF TM 50 tocilizumab 50 DexaSite 50 prulifloxacin 50 Linjeta TM 50 attain statistical significance 50 PDP MLR 50 fosamprenavir 50 anthracycline containing 50 non metastatic resectable 50 azacytidine 50 BETAS 50 prospective multicenter randomized 50 non selective NSAIDs 50 antidiabetic drugs 50 rALLy trial 50 double blinded placebo 50 Rilonacept 50 logistic regression models 50 TG# [001] 50 intravesical instillation 50 abiraterone acetate 50 AVERROES 50 Phase #b/#a trial 50 delta isoform 50 octreotide acetate 50 FOLFOX6 50 EndoTAG TM -1 50 locoregional disease 50 ACCORD Lipid 50 subcutaneous SC 50 Resolute DES 50 tipranavir 50 Aplenzin 50 OvaRex 50 comparator arm 50 Delafloxacin 50 Aspergillus nidulans 50 pancreatic prostate 50 MVA BN R 50 HuMax CD4 50 isatoribine 50 metformin sulfonylurea 50 nilotinib 50 PROLARIS 50 PNP inhibitor 50 CRp 50 relapsed ovarian cancer 50 5 lipoxygenase inhibitor 50 AChE inhibitors 50 TriRima 50 lenalidomide Revlimid ® 50 PRT# 50 either acutely decompensated 50 vinorelbine tartrate 50 multivariate regression 50 iodixanol 50 MedTone inhaler 50 fluorouracil 50 GERD migraine headaches 50 gefitinib 50 Eloxatin R 50 thetreatment 50 Peginterferon 50 enfuvirtide 50 T#I [002] 50 TNF alpha inhibitor 50 mg/m2 dose 50 REOPRO 50 metastatic renal cell carcinoma 50 AEGR 50 Effexor venlafaxine 50 TKB# 50 genotypic 50 mso font pitch 50 TO AVOID PREGNANCY WHILE 50 CINQUIL 50 confirmatory clinical 50 Platinol 50 Navelbine 50 StemEx 50 investigational humanized monoclonal antibody 50 pegylated interferon alfa 2b 50 cytotoxicity 50 glufosfamide 50 postmenopausal osteoporotic women 50 ULORIC 50 rHuEPO 50 urodynamic 50 oral FTY# 50 TYKERB 50 doxorubicin docetaxel 50 Moxifloxacin 50 Multivariable logistic regression 50 Introductory teaser rates 50 inhibit EGFR 50 Multivariate analysis 50 Septin9 50 tipranavir r 50 microRNA biomarkers 50 candidate TNFerade biologic 50 Oncotype DX breast cancer 50 ximelagatran 50 salmeterol fluticasone 50 radiolabeled 50 dosing regimens 50 bevacizumab Avastin ® 50 LungExpress Dx TM 50 glycated hemoglobin levels 50 M# rationally 50 Vaxfectin 50 ARCOXIA 50 latanoprost 50 mcg albinterferon alfa 2b 50 PDE4 inhibitor 50 TYGACIL 50 PEG interferon 50 anti arrhythmic 50 virologic response 50 PURE proprietary 50 antitumour 50 DITPA 50 Trofex 50 GLPG# 50 anticoagulant reversing agent 50 metabolite concentrations 50 clinico pathological 50 PLX STROKE targeting